肿瘤细胞治疗研究
英文原题：Two Drugs, One Stunning Myeloma Result.
通过将靶向BCMA的T细胞衔接器与抗CD38抗体配对使用，研究人员在复发骨髓瘤患者中实现了显著深度的缓解，并大幅降低了复发风险。
通过将靶向BCMA的T细胞衔接器与抗CD38抗体配对使用，研究者在复发骨髓瘤患者中实现了显著深度的缓解，并大幅降低了复发风险。结果提示，这种双重免疫导向策略可能挑战当前的治疗排序，包括何时部署工程化T细胞疗法。
By pairing a BCMA-targeted T-cell engager with an anti-CD38 antibody, researchers achieved strikingly deep remissions and sharply reduced relapse risk in patients with relapsed myeloma. The results suggest this dual immune-directed strategy could challenge current treatment sequencing, including when to deploy engineered T-cell therapies.
MEMBER ACCOUNT
登录成功会直接打开下一页。
